3//SEC Filing
Atlas Venture Associates IX, L.P. 3
Accession 0001209191-18-025385
CIK 0001718108other
Filed
Apr 17, 8:00 PM ET
Accepted
Apr 18, 4:55 PM ET
Size
9.5 KB
Accession
0001209191-18-025385
Insider Transaction Report
Form 3
Atlas Venture Associates IX, LLC
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (3,181,817 underlying)- 1,363,636
Common Stock
Atlas Venture Fund IX, L.P.
10% Owner
Holdings
- 1,363,636
Common Stock
Series A Preferred Stock
→ Common Stock (3,181,817 underlying)
Atlas Venture Associates IX, L.P.
10% Owner
Holdings
- 1,363,636
Common Stock
Series A Preferred Stock
→ Common Stock (3,181,817 underlying)
Footnotes (3)
- [F1]The number of shares reported reflects a 2.2-for-1 reverse stock split of the Issuer's Common Stock effected on April 6, 2018.
- [F2]The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.
- [F3]The Series A Preferred Stock is convertible on a 2.2-for-1 basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date.
Documents
Issuer
Surface Oncology, Inc.
CIK 0001718108
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001671208
Filing Metadata
- Form type
- 3
- Filed
- Apr 17, 8:00 PM ET
- Accepted
- Apr 18, 4:55 PM ET
- Size
- 9.5 KB